公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study | CHIA-CHI LIN ; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU | Oncologist | 5 | 4 | |
2021 | Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab | Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU ; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. | British Journal of Cancer | 37 | 35 | |
2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 19 | 17 | |
2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 25 | 19 |